{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:53:59Z","timestamp":1783612439213,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ejca.2025.115472","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T15:19:23Z","timestamp":1745594363000},"page":"115472","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Risk of secondary myelodysplastic syndromes and acute myeloid leukaemia following poly(ADP-ribose) polymerase inhibitor treatment for advanced-stage recurrent ovarian cancer: A retrospective cohort study in England"],"prefix":"10.1016","volume":"222","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6759-4701","authenticated-orcid":false,"given":"Luke","family":"Steventon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1125-405X","authenticated-orcid":false,"given":"Shibani","family":"Nicum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6669-9411","authenticated-orcid":false,"given":"Pinkie","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8645-1942","authenticated-orcid":false,"given":"Kenneth","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8787-4904","authenticated-orcid":false,"given":"David","family":"Dodwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6085-8449","authenticated-orcid":false,"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2096-4840","authenticated-orcid":false,"given":"Apini","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1941-6444","authenticated-orcid":false,"given":"Ben","family":"Pickwell-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8840-7267","authenticated-orcid":false,"given":"Li","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115472_bib1","unstructured":"CRUK. Cancer incidence statistics https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/incidence: Cancer Research UK; 2018 [Available from: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/incidence."},{"issue":"10","key":"10.1016\/j.ejca.2025.115472_bib2","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.21873\/anticanres.15281","article-title":"Randomized clinical trials and real world prospective observational studies on bevacizumab, PARP inhibitors, and immune checkpoint inhibitors in the first-line treatment of advanced ovarian carcinoma: a critical review","volume":"41","author":"Gadducci","year":"2021","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2025.115472_bib3","unstructured":"EMA. Lynparza. European Medicines Agency; 2024."},{"issue":"22","key":"10.1016\/j.ejca.2025.115472_bib4","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"issue":"10106","key":"10.1016\/j.ejca.2025.115472_bib5","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ejca.2025.115472_bib6","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jama.2022.14578","article-title":"Diagnosis and treatment of myelodysplastic syndromes: a review","volume":"328","author":"Sekeres","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2025.115472_bib7","doi-asserted-by":"crossref","unstructured":"Gupta B., Sait S.N., Block A.W., Ford L.A., Moysich K.B., Baer M.R. Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) following treatment for ovarian cancer. Journal of Clinical Oncology.25(18_suppl):17506-.","DOI":"10.1200\/jco.2007.25.18_suppl.17506"},{"issue":"3","key":"10.1016\/j.ejca.2025.115472_bib8","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1159\/000521160","article-title":"A case of recurrent ovarian cancer and therapy-related acute myeloid leukemia treated with azacitidine","volume":"14","author":"Ando","year":"2021","journal-title":"Case Rep Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2025.115472_bib9","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2352-3026(20)30360-4","article-title":"Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database","volume":"8","author":"Morice","year":"2021","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.ejca.2025.115472_bib10","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2025.115472_bib11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJM199902043400504","article-title":"Risk of leukemia after platinum-based chemotherapy for ovarian cancer","volume":"340","author":"Travis","year":"1999","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2025.115472_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyz076","article-title":"Data resource profile: national cancer registration dataset in England","volume":"49","author":"Henson","year":"2020","journal-title":"Int J Epidemiol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115472_bib13","article-title":"Data resource profile: the systemic anti-cancer therapy (SACT) dataset","volume":"49","author":"Bright","year":"2020","journal-title":"Int J Epidemiol"},{"issue":"4","key":"10.1016\/j.ejca.2025.115472_bib14","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyx015","article-title":"Data resource profile: hospital episode statistics admitted patient care (HES APC)","volume":"46","author":"Herbert","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.ejca.2025.115472_bib15","unstructured":"International Classification of Diseases, Tenth Revision [Internet]. CDC. 2019. Available from: https:\/\/icd.who.int\/browse10\/2019\/en."},{"issue":"10","key":"10.1016\/j.ejca.2025.115472_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040297","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration","volume":"4","author":"Vandenbroucke","year":"2007","journal-title":"PLOS Med"},{"key":"10.1016\/j.ejca.2025.115472_bib17","unstructured":"NICE. Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy nice.org.uk2024 [Available from: https:\/\/www.nice.org.uk\/guidance\/ta962\/chapter\/2-Information-about-olaparib."},{"issue":"4","key":"10.1016\/j.ejca.2025.115472_bib18","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1136\/ijgc-2022-004190","article-title":"Myeloid neoplasms post PARP inhibitors for ovarian cancer","volume":"33","author":"Caruso","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ejca.2025.115472_bib19","unstructured":"BMJ. A glossary of EBM terms bestpractice.bmj.com2024 [Available from: https:\/\/bestpractice.bmj.com\/info\/us\/toolkit\/ebm-tools\/a-glossary-of-ebm-terms\/."},{"issue":"2","key":"10.1016\/j.ejca.2025.115472_bib20","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1016\/S2352-3026(20)30375-6","article-title":"PARP inhibitors\u2014understanding the risk of myelodysplastic syndrome and acute myeloid leukaemia","volume":"8","author":"Tinker","year":"2021","journal-title":"Lancet Haematol"},{"issue":"24","key":"10.1016\/j.ejca.2025.115472_bib21","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.3390\/cancers13246385","article-title":"PARP inhibitors and myeloid neoplasms: a double-edged sword","volume":"13","author":"Csizmar","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2025.115472_bib22","article-title":"Myelodysplastic syndrome\/acute myeloid leukemia following the use of poly-ADP ribose polymerase (PARP) inhibitors: a real-world analysis of postmarketing surveillance data","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ejca.2025.115472_bib23","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0090-8258(22)01244-6","article-title":"Final overall survival results from SOLO3: phase III trial assessing olaparib monotherapy versus non-platinum chemotherapy in heavily pretreated patients with germline BRCA1 - and\/or BRCA2-mutated platinum-sensitive relapsed ovarian cancer (026)","volume":"166","author":"Penson","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2025.115472_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2023.06.508","article-title":"Final overall survival and long-term safety in the ENGOT-OV16\/NOVA phase III trial of niraparib in patients with recurrent ovarian cancer (LBA 6)","volume":"176","author":"Matulonis","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2025.115472_bib25","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.19.02745","article-title":"Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1\/2 mutation (SOLO3): a randomized phase III trial","volume":"38","author":"Penson","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.ejca.2025.115472_bib26","article-title":"ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC)","volume":"24","author":"Coleman","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2025.115472_bib27","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyz076","article-title":"Data resource profile: national cancer registration dataset in England","volume":"49","author":"Henson","year":"2019","journal-title":"Int J Epidemiol"},{"issue":"32","key":"10.1016\/j.ejca.2025.115472_bib28","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1200\/JCO.18.02238","article-title":"Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16\/NOVA trial","volume":"37","author":"Del Campo","year":"2019","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1016\/j.ejca.2025.115492","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000}}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925002539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925002539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T11:58:53Z","timestamp":1749815933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925002539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":28,"alternative-id":["S0959804925002539"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115472","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of secondary myelodysplastic syndromes and acute myeloid leukaemia following poly(ADP-ribose) polymerase inhibitor treatment for advanced-stage recurrent ovarian cancer: A retrospective cohort study in England","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115472","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115472"}}